Epidarex Capital is an independent, international, and privately-held investment firm that specializes in early-stage life science and health technology companies. The firm focuses on providing capital and strategic support to companies developing innovative technologies and therapeutics with the potential to transform the future of healthcare.

Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets.  Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.

Sirakoss

Confluence Life Sciences

Apellis Pharmaceuticals

Epidarex Capital

Our Chief Medical Officer Catherine (Cass) Kelleher, MD spoke to In Vivo about her role at Mironid, the unmet medical need in ADPKD and the potential impact of our LoAc® small molecule in development for the treatment of ADPKD.
 
Read the full Q&A here: https://lnkd.in/etuv4rz5
 
#KidneyDisease #RareDisease #Biopharma #DrugDevelopment

Congratulations to Epidarex portfolio company Lario Therapeutics on winning the ‘Company Making a Difference Award’ at the CDLK5 Forum. This is an exciting time for Lario Therapeutics and Epidarex Capital.

Epidarex is delighted to support this initiative!

We are delighted that five Epidarex portfolio companies have been showcased among the 50 companies in PwC UK’s 2023 'Life Sciences Future 50' report, illustrating the world-class science and innovation that Epidarex is funding across the UK.

We are delighted to welcome Kevin Lee to the Macomics board!

Great to see that NodThera has commenced a Phase Ib/IIa cardiovascular risk study with their lead brain penetrant NLRP3 inhibitor.

We’re pleased to announce that Matthew Miessau has been promoted to Principal. 

Matthew joined Epidarex as an intern and has been an integral part of the team since the firm’s early days. He has been actively involved in deal sourcing including expanding Epidarex’s reach and relationships with key universities in emerging hubs in the US. He has also focused on conducting due diligence and portfolio management on both sides of the Atlantic. Matthew is a frequent speaker, mentor and instructor acting as an ambassador for Epidarex and a champion of the local ecosystem.

Congratulations Matthew!

Epidarex Venture Partner Terri Burke is delighted to be participating in this week’s MedTech Conference in Anaheim, California.

Congratulations to Apellis Pharmaceuticals on receiving FDA approval of the EMPAVELI® Injector.

COM:EPIDAREX

Epidarex Capital

Analysis Not Available